Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:heteroarene
go back to main search page
Accession:CHEBI:33833 term browser browse the term
Definition:A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2).
Synonyms:exact_synonym: heteroarenes
 related_synonym: hetarenes



show annotations for term's descendants           Sort by:
1,10-phenanthroline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ANPEP alanyl aminopeptidase, membrane multiple interactions
decreases activity
EXP Edetic Acid promotes the reaction [1,10-phenanthroline results in decreased activity of ANPEP protein] CTD PMID:17109655 NCBI chr 7:55,351,081...55,373,856
Ensembl chr 7:55,351,087...55,373,881
JBrowse link
G ENPEP glutamyl aminopeptidase multiple interactions EXP 1,10-phenanthroline inhibits the reaction [ENPEP protein results in increased hydrolysis of Aspartame] CTD PMID:8141778 NCBI chr 8:111,765,839...111,858,349
Ensembl chr 8:111,748,514...111,858,510
JBrowse link
3',5'-cyclic AMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP7B ATPase copper transporting beta multiple interactions EXP Cyclic AMP inhibits the reaction [Copper binds to ATP7B protein] CTD PMID:21084060 NCBI chr11:15,892,549...15,942,070
Ensembl chr11:15,876,612...15,942,064
JBrowse link
G CALCB calcitonin-related polypeptide beta increases abundance EXP CALCA protein results in increased abundance of Cyclic AMP CTD PMID:18463244 NCBI chr 2:44,043,135...44,048,651 JBrowse link
G DUOX2 dual oxidase 2 increases expression EXP Cyclic AMP results in increased expression of DUOX2 mRNA CTD PMID:10601291 NCBI chr 1:126,620,468...126,641,406
Ensembl chr 1:126,620,510...126,641,406
JBrowse link
G GCG glucagon affects response to substance
increases abundance
EXP Cyclic AMP affects the susceptibility to GCG protein
GCG protein results in increased abundance of Cyclic AMP
CTD PMID:6253273 NCBI chr15:68,800,557...68,810,268
Ensembl chr15:68,800,560...68,810,242
JBrowse link
G GNRH1 gonadotropin releasing hormone 1 multiple interactions
increases abundance
EXP [Cobalt binds to GNRH1 protein] which results in increased abundance of Cyclic AMP
GNRH1 protein results in increased abundance of Cyclic AMP
CTD PMID:15833593 NCBI chr14:9,442,971...9,447,521
Ensembl chr14:9,442,971...9,453,035
JBrowse link
3',5'-cyclic GMP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G PDE5A phosphodiesterase 5A increases degradation EXP PDE5 protein results in increased degradation of Cyclic GMP CTD PMID:18669600 NCBI chr 8:104,270,858...104,420,955
Ensembl chr 8:104,270,881...104,420,953
JBrowse link
G PDE6C phosphodiesterase 6C increases degradation EXP PDE6C protein results in increased degradation of Cyclic GMP CTD PMID:18669600 NCBI chr14:105,010,974...105,122,628
Ensembl chr14:105,050,691...105,122,421
JBrowse link
G PRKG1 protein kinase cGMP-dependent 1 increases activity EXP Cyclic GMP results in increased activity of PRKG1 protein CTD PMID:18037907 NCBI chr14:97,558,531...98,793,080
Ensembl chr14:97,558,533...98,793,010
JBrowse link
3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALOX5AP arachidonate 5-lipoxygenase activating protein multiple interactions EXP MK-886 inhibits the reaction [aristolochic acid I results in increased expression of ALOX5AP protein] CTD PMID:21658425 NCBI chr11:7,371,328...7,438,111
Ensembl chr11:7,411,644...7,438,108
JBrowse link
G CASP3 caspase 3 multiple interactions EXP MK-886 inhibits the reaction [aristolochic acid I results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:21658425 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
JBrowse link
3-\{1-[3-(dimethylamino)propyl]-1H-indol-3-yl\}-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HIF1A hypoxia inducible factor 1 subunit alpha multiple interactions EXP bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of HIF1A mRNA] CTD PMID:15089098 NCBI chr 1:190,625,436...190,673,926
Ensembl chr 1:190,625,244...190,674,845
JBrowse link
G VEGFA vascular endothelial growth factor A multiple interactions EXP bisindolylmaleimide I inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA] CTD PMID:15089098 NCBI chr 7:38,746,393...38,762,282
Ensembl chr 7:38,746,052...38,761,366
JBrowse link
3-methyladenine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BAX mRNA] CTD PMID:28803810 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
JBrowse link
G BECN1 beclin 1 multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of BECN1 protein] CTD PMID:28803810 PMID:34811946 NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
JBrowse link
G CASP3 caspase 3 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of CASP3 protein] CTD PMID:28803810 PMID:30287338 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
JBrowse link
G CASP8 caspase 8 multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased cleavage of CASP8 protein] CTD PMID:28803810 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
JBrowse link
G CAT catalase multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein] CTD PMID:34811946 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CYCS cytochrome c, somatic multiple interactions EXP 3-methyladenine inhibits the reaction [Zinc Sulfate results in increased expression of CYCS mRNA] CTD PMID:28803810 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G DCTN4 dynactin subunit 4 multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA] CTD PMID:34811946 NCBI chr 2:151,681,001...151,713,923
Ensembl chr 2:151,681,003...151,783,746
JBrowse link
G FGD4 FYVE, RhoGEF and PH domain containing 4 multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]] CTD PMID:34811946 NCBI chr 5:41,571,054...41,636,058
Ensembl chr 5:41,570,282...41,636,028
JBrowse link
G FIS1 fission, mitochondrial 1 multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]] CTD PMID:34811946 NCBI chr 3:8,938,250...8,942,102
Ensembl chr 3:8,937,453...8,946,955
JBrowse link
G GPX1 glutathione peroxidase 1 multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA] CTD PMID:34811946 NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
JBrowse link
G LAMP2 lysosomal associated membrane protein 2 decreases expression EXP 3-methyladenine results in decreased expression of LAMP2 protein CTD PMID:36754226 NCBI chr  X:98,586,718...98,623,939
Ensembl chr  X:98,556,710...98,623,940
JBrowse link
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions
decreases lipidation
EXP 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; Benzo(a)pyrene promotes the reaction [3-methyladenine results in decreased lipidation of MAP1LC3B protein] CTD PMID:34811946 PMID:36754226 NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
JBrowse link
G MKI67 marker of proliferation Ki-67 multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]] CTD PMID:34811946 NCBI chr14:137,266,622...137,296,312 JBrowse link
G MYD88 MYD88 innate immune signal transduction adaptor multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the activity of CAT protein]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of BECN1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of DCTN4 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of GPX1 mRNA]; 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of MKI67 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of DNM1L protein]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of FIS1 mRNA]]; 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of BECN1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the lipidation of MAP1LC3B protein]]; 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] CTD PMID:34811946 NCBI chr13:22,976,951...22,979,568
Ensembl chr13:22,966,137...22,983,109
JBrowse link
G OPA1 OPA1 mitochondrial dynamin like GTPase multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of OPA1 mRNA]] CTD PMID:34811946 NCBI chr13:130,624,771...130,718,345
Ensembl chr13:130,624,796...130,719,083
JBrowse link
G PARP1 poly(ADP-ribose) polymerase 1 multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in increased expression of PARP1 protein]]; 3-methyladenine promotes the reaction [ochratoxin A results in increased cleavage of PARP1 protein] CTD PMID:30287338 PMID:34811946 NCBI chr10:14,203,157...14,241,164
Ensembl chr10:14,203,160...14,241,196
JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions EXP 3-methyladenine affects the reaction [[MYD88 protein affects the susceptibility to Paraquat] which affects the expression of SOD1 mRNA] CTD PMID:34811946 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
JBrowse link
G SQSTM1 sequestosome 1 multiple interactions EXP 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [Zinc Sulfate results in decreased expression of SQSTM1 protein] CTD PMID:28803810 PMID:34811946 NCBI chr 2:78,752,768...78,763,998
Ensembl chr 2:78,752,771...78,763,938
JBrowse link
G TOMM20 translocase of outer mitochondrial membrane 20 multiple interactions EXP 3-methyladenine affects the reaction [MYD88 protein affects the reaction [Paraquat results in decreased expression of TOMM20 protein]] CTD PMID:34811946 NCBI chr14:56,113,087...56,127,686
Ensembl chr14:56,113,192...56,127,677
JBrowse link
G TP53 tumor protein p53 multiple interactions EXP 3-methyladenine affects the reaction [Paraquat affects the reaction [MYD88 protein affects the phosphorylation of TP53 protein]] CTD PMID:34811946 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
JBrowse link
5-aza-2'-deoxycytidine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G DNMT1 DNA methyltransferase 1 multiple interactions EXP Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 mRNA]; Decitabine inhibits the reaction [ochratoxin A results in increased expression of DNMT1 protein] CTD PMID:29080797 PMID:30923867 NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
JBrowse link
G H2AX H2A.X variant histone multiple interactions EXP Decitabine inhibits the reaction [ochratoxin A results in increased expression of H2AX protein] CTD PMID:30923867 NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
JBrowse link
G JAK2 Janus kinase 2 multiple interactions
decreases phosphorylation
EXP Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of JAK2 protein]
Decitabine results in decreased phosphorylation of JAK2 protein
CTD PMID:30923867 NCBI chr 1:216,849,744...217,002,310
Ensembl chr 1:216,848,689...217,002,148
JBrowse link
G NEIL1 nei like DNA glycosylase 1 multiple interactions
increases expression
EXP Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL1 mRNA]
Decitabine results in increased expression of NEIL1 mRNA
CTD PMID:30923867 NCBI chr 7:58,261,761...58,269,001
Ensembl chr 7:58,261,769...58,268,522
JBrowse link
G NEIL3 nei like DNA glycosylase 3 multiple interactions
increases expression
EXP Decitabine inhibits the reaction [ochratoxin A results in decreased expression of NEIL3 mRNA]
Decitabine results in increased expression of NEIL3 mRNA
CTD PMID:30923867 NCBI chr15:39,416,073...39,632,313
Ensembl chr15:39,581,856...39,632,308
JBrowse link
G OGG1 8-oxoguanine DNA glycosylase increases expression
multiple interactions
EXP Decitabine results in increased expression of OGG1 mRNA
Decitabine inhibits the reaction [ochratoxin A results in decreased expression of OGG1 mRNA]
CTD PMID:30923867 NCBI chr13:66,038,669...66,045,478 JBrowse link
G SOCS3 suppressor of cytokine signaling 3 multiple interactions EXP Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 mRNA]; Decitabine promotes the reaction [ochratoxin A results in increased expression of SOCS3 protein] CTD PMID:30923867 NCBI chr12:3,643,832...3,647,015
Ensembl chr12:3,643,929...3,647,009
JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions EXP Decitabine inhibits the reaction [ochratoxin A results in increased phosphorylation of STAT3 protein] CTD PMID:30923867 NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992
JBrowse link
5-methyl-pyrazole-3-carboxylic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G DAO D-amino acid oxidase decreases activity EXP 5-methylpyrazole-3-carboxylic acid results in decreased activity of DAO protein CTD PMID:20952482 NCBI chr14:41,931,549...41,950,628
Ensembl chr14:41,931,541...41,950,633
JBrowse link
adenosine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G MYL9 myosin light chain 9 decreases phosphorylation
multiple interactions
EXP Adenosine results in decreased phosphorylation of MYL9 protein
8-phenyltheophylline inhibits the reaction [Adenosine results in decreased phosphorylation of MYL9 protein]
CTD PMID:10942722 NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
JBrowse link
ageladine A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CSNK1A1 casein kinase 1 alpha 1 decreases activity
affects activity
EXP Ageladine A analog results in decreased activity of CSNK1A1 protein
Ageladine A affects the activity of CSNK1A1 protein
CTD PMID:21413800 NCBI chr 2:150,612,845...150,662,431
Ensembl chr 2:150,612,077...150,662,284
JBrowse link
ATP term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BCL2 BCL2 apoptosis regulator increases expression
multiple interactions
EXP Adenosine Triphosphate results in increased expression of BCL2 protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of BCL2 protein]
CTD PMID:17997382 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
JBrowse link
G CASP8 caspase 8 increases activity
multiple interactions
EXP Adenosine Triphosphate results in increased activity of CASP8 protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased activity of CASP8 protein]
CTD PMID:17997382 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
JBrowse link
G CYCS cytochrome c, somatic affects localization
multiple interactions
EXP Adenosine Triphosphate affects the localization of CYCS protein
[Calcium co-treated with Phosphates co-treated with Adenosine Triphosphate] affects the localization of CYCS protein; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate affects the localization of CYCS protein]
CTD PMID:16489745 PMID:17997382 NCBI chr18:47,169,921...47,172,212
Ensembl chr18:47,169,866...47,173,866
JBrowse link
G MYL9 myosin light chain 9 decreases phosphorylation
multiple interactions
EXP Adenosine Triphosphate results in decreased phosphorylation of MYL9 protein
1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid inhibits the reaction [Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]]; Adenosine Triphosphate promotes the reaction [calyculin A results in increased phosphorylation of MYL9 protein]
CTD PMID:10942722 NCBI chr17:39,788,165...39,795,240
Ensembl chr17:39,788,199...39,795,293
JBrowse link
G TNF tumor necrosis factor increases expression
multiple interactions
EXP Adenosine Triphosphate results in increased expression of TNF protein
tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [Adenosine Triphosphate results in increased expression of TNF protein]
CTD PMID:17997382 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
JBrowse link
bilirubin IXalpha term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CASP3 caspase 3 multiple interactions EXP Bilirubin inhibits the reaction [Excitatory Amino Acid Agents results in increased activity of CASP3 protein] CTD PMID:16371440 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
JBrowse link
brimonidine tartrate term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CREB1 cAMP responsive element binding protein 1 increases phosphorylation
multiple interactions
EXP Brimonidine Tartrate results in increased phosphorylation of CREB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Brimonidine Tartrate results in increased phosphorylation of CREB1 protein]
CTD PMID:17680988 NCBI chr15:110,705,548...110,773,037
Ensembl chr15:110,705,496...110,771,728
JBrowse link
bucladesine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATP1A1 ATPase Na+/K+ transporting subunit alpha 1 increases expression EXP Bucladesine results in increased expression of ATP1A1 protein CTD PMID:28438630 NCBI chr 4:104,353,506...104,384,321
Ensembl chr 4:104,353,508...104,384,547
JBrowse link
caffeine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G RYR1 ryanodine receptor 1 increases activity
multiple interactions
EXP Caffeine results in increased activity of RYR1 protein; Caffeine results in increased activity of RYR1 protein mutant form
Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]; Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein mutant form]]; Dantrolene inhibits the reaction [Caffeine promotes the reaction [Ryanodine binds to RYR1 protein]]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein mutant form]; Dantrolene inhibits the reaction [Caffeine results in increased activity of RYR1 protein]
CTD PMID:11278295 NCBI chr 6:47,339,759...47,458,457
Ensembl chr 6:47,343,768...47,458,458
JBrowse link
crizotinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NTRK1 neurotrophic receptor tyrosine kinase 1 decreases activity EXP Crizotinib results in decreased activity of NTRK1 protein CTD PMID:21812414 NCBI chr 4:93,219,509...93,237,944
Ensembl chr 4:93,219,516...93,255,981
JBrowse link
G NTRK2 neurotrophic receptor tyrosine kinase 2 decreases activity EXP Crizotinib results in decreased activity of NTRK2 protein CTD PMID:21812414 NCBI chr10:30,030,050...30,429,938
Ensembl chr10:30,033,405...30,429,882
JBrowse link
cyanocob(III)alamin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein CTD PMID:29129240 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G DNMT1 DNA methyltransferase 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA CTD PMID:28445388 NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
JBrowse link
G DNMT3A DNA methyltransferase 3 alpha multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA CTD PMID:28445388 NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
JBrowse link
G GPX1 glutathione peroxidase 1 multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA CTD PMID:29129240 NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
JBrowse link
G MTHFR methylenetetrahydrofolate reductase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA CTD PMID:28445388 NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
JBrowse link
G SI sucrase-isomaltase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA CTD PMID:28445388 NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
JBrowse link
G SLC15A1 solute carrier family 15 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA CTD PMID:28445388 NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
JBrowse link
G SLC5A1 solute carrier family 5 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA CTD PMID:28445388 NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA CTD PMID:29129240 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
JBrowse link
ferroheme b term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMOX1 heme oxygenase 1 increases metabolic processing
multiple interactions
EXP HMOX1 protein results in increased metabolism of Heme
[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]
CTD PMID:16751286
folic acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] promotes the reaction [bisphenol A results in decreased expression of CAT protein]; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT mRNA; [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of CAT protein CTD PMID:29129240 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CBS cystathionine beta-synthase multiple interactions
increases activity
EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of CBS protein
Folic Acid deficiency results in increased activity of CBS protein
CTD PMID:16792574 NCBI chr13:206,205,942...206,231,363
Ensembl chr13:206,205,946...206,230,248
JBrowse link
G CSF2 colony stimulating factor 2 multiple interactions EXP [Folic Acid co-treated with Glycine] results in decreased expression of CSF2 mRNA CTD PMID:14662146 NCBI chr 2:134,354,724...134,357,155
Ensembl chr 2:134,354,724...134,357,155
JBrowse link
G CTH cystathionine gamma-lyase multiple interactions EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of CTH protein CTD PMID:16792574 NCBI chr 6:142,454,922...142,486,352
Ensembl chr 6:142,454,914...142,486,367
JBrowse link
G DNMT1 DNA methyltransferase 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT1 mRNA CTD PMID:28445388 NCBI chr 2:68,981,564...69,040,364
Ensembl chr 2:68,981,566...69,029,844
JBrowse link
G DNMT3A DNA methyltransferase 3 alpha multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of DNMT3A mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of DNMT3A mRNA CTD PMID:28445388 NCBI chr 3:113,501,972...113,609,148
Ensembl chr 3:113,528,926...113,603,087
JBrowse link
G GCLC glutamate-cysteine ligase catalytic subunit multiple interactions EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of GCLC protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GCLC mRNA CTD PMID:16792574 NCBI chr 7:27,209,565...27,253,535
Ensembl chr 7:27,209,565...27,253,530
JBrowse link
G GPX1 glutathione peroxidase 1 multiple interactions EXP [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of GPX1 mRNA; [bisphenol A co-treated with [Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12]] results in increased expression of GPX1 mRNA CTD PMID:29129240 NCBI chr13:31,916,269...31,917,337
Ensembl chr13:31,916,246...31,917,433
JBrowse link
G GSR glutathione-disulfide reductase multiple interactions
increases activity
increases expression
EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSR protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSR mRNA
Folic Acid deficiency results in increased activity of GSR protein
Folic Acid deficiency results in increased expression of GSR mRNA
CTD PMID:16792574 NCBI chr15:54,382,564...54,433,989
Ensembl chr15:54,382,567...54,433,984
JBrowse link
G GSS glutathione synthetase multiple interactions EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of GSS protein; [Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSS mRNA CTD PMID:16792574 NCBI chr17:38,316,199...38,342,253
Ensembl chr17:38,312,720...38,342,298
JBrowse link
G GSTA1 glutathione S-transferase alpha 1 increases expression
multiple interactions
EXP Folic Acid deficiency results in increased expression of GSTA1 mRNA
[Ethanol co-treated with Folic Acid deficiency] results in increased expression of GSTA1 mRNA
CTD PMID:16792574 NCBI chr 7:46,538,743...46,550,781
Ensembl chr 7:46,538,032...46,548,670
JBrowse link
G GYS1 glycogen synthase 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Folic Acid co-treated with bisphenol A] results in increased methylation of GYS1 promoter; [Betaine co-treated with Choline co-treated with Folic Acid] results in decreased expression of GYS1 mRNA; [Betaine co-treated with Choline co-treated with Folic Acid] results in increased methylation of GYS1 promoter CTD PMID:29065941 NCBI chr 6:54,234,600...54,250,211
Ensembl chr 6:54,233,050...54,250,261
JBrowse link
G LDHA lactate dehydrogenase A multiple interactions EXP [bisphenol A co-treated with Choline co-treated with Folic Acid co-treated with Betaine] results in decreased methylation of LDHA promoter CTD PMID:29065941 NCBI chr 2:40,814,163...40,827,284
Ensembl chr 2:40,814,169...40,826,715
JBrowse link
G MTHFR methylenetetrahydrofolate reductase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of MTHFR mRNA CTD PMID:28445388 NCBI chr 6:71,863,637...71,882,118
Ensembl chr 6:71,863,637...71,881,820
JBrowse link
G PTGS1 prostaglandin-endoperoxide synthase 1 multiple interactions EXP [Folic Acid co-treated with Glycine] results in decreased expression of PTGS1 CTD PMID:14662146 NCBI chr 1:262,456,106...262,482,159
Ensembl chr 1:262,456,155...262,483,035
JBrowse link
G PTGS2 prostaglandin-endoperoxide synthase 2 multiple interactions EXP [Folic Acid co-treated with Glycine] results in increased expression of PTGS2 CTD PMID:14662146 NCBI chr 9:127,850,164...127,858,866
Ensembl chr 9:127,850,015...127,858,884
JBrowse link
G SI sucrase-isomaltase multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SI mRNA CTD PMID:28445388 NCBI chr13:104,296,281...104,379,558
Ensembl chr13:104,296,283...104,379,478
JBrowse link
G SLC15A1 solute carrier family 15 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased expression of SLC15A1 mRNA]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] inhibits the reaction [bisphenol A results in decreased methylation of SLC15A1 promoter]; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC15A1 mRNA CTD PMID:28445388 NCBI chr11:67,652,808...67,690,457
Ensembl chr11:67,652,193...67,710,933
JBrowse link
G SLC5A1 solute carrier family 5 member 1 multiple interactions EXP [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid co-treated with bisphenol A] results in increased expression of SLC5A1 mRNA; [Betaine co-treated with Choline co-treated with Vitamin B 12 co-treated with Folic Acid] results in increased expression of SLC5A1 mRNA CTD PMID:28445388 NCBI chr14:48,566,400...48,704,145
Ensembl chr14:48,628,224...48,705,841
JBrowse link
G SOD1 superoxide dismutase 1 decreases activity
multiple interactions
EXP Folic Acid deficiency results in decreased activity of SOD1 protein
[Betaine co-treated with Folic Acid co-treated with Choline co-treated with Vitamin B 12] results in increased expression of SOD1 mRNA; [Ethanol co-treated with Folic Acid deficiency] results in decreased activity of SOD1 protein
CTD PMID:16792574 PMID:29129240 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
JBrowse link
G SOD2 superoxide dismutase 2 multiple interactions
increases activity
EXP [Ethanol co-treated with Folic Acid deficiency] results in increased activity of SOD2 protein
Folic Acid deficiency results in increased activity of SOD2 protein; Folic Acid results in increased activity of SOD2 protein
CTD PMID:16792574 PMID:22889112 NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
JBrowse link
GSK2656157 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ATF4 activating transcription factor 4 multiple interactions EXP GSK2656157 inhibits the reaction [deoxynivalenol results in increased expression of ATF4 protein] CTD PMID:37442268 NCBI chr 5:8,742,964...8,745,752
Ensembl chr 5:8,742,967...8,745,368
JBrowse link
G DDIT3 DNA damage inducible transcript 3 multiple interactions EXP GSK2656157 inhibits the reaction [deoxynivalenol results in increased expression of DDIT3 protein] CTD PMID:37442268 NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
JBrowse link
G EIF2A eukaryotic translation initiation factor 2A multiple interactions EXP GSK2656157 inhibits the reaction [deoxynivalenol results in increased phosphorylation of EIF2A protein] CTD PMID:37442268 NCBI chr13:90,761,453...90,804,274
Ensembl chr13:90,761,465...90,804,274
JBrowse link
G EIF2AK3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions EXP GSK2656157 inhibits the reaction [deoxynivalenol results in increased phosphorylation of EIF2AK3 protein] CTD PMID:37442268 NCBI chr 3:57,423,894...57,506,247
Ensembl chr 3:57,423,943...57,506,245
JBrowse link
heme b term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HMOX1 heme oxygenase 1 increases metabolic processing
multiple interactions
EXP HMOX1 protein results in increased metabolism of Heme
[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide; chromium mesoporphyrin inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]; tin protoporphyrin IX inhibits the reaction [[HMOX1 protein results in increased metabolism of Heme] which results in increased abundance of Carbon Monoxide]
CTD PMID:16751286
histamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HRH2 histamine receptor H2 multiple interactions EXP [Histamine affects the activity of HRH2 protein] which affects the secretion of Chlorides CTD PMID:12665126 NCBI chr 2:81,883,670...81,932,464
Ensembl chr 2:81,883,673...81,932,275
JBrowse link
hypoxanthine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CAT catalase multiple interactions EXP CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein] CTD PMID:21984542 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G XDH xanthine dehydrogenase multiple interactions EXP [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Hydrogen Peroxide; [Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Superoxides; CAT protein inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; CAT protein results in decreased activity of [Hypoxanthine co-treated with XDH protein]; tempol inhibits the reaction [[Hypoxanthine co-treated with XDH protein] results in increased chemical synthesis of Carbon Monoxide]; tempol results in decreased activity of [Hypoxanthine co-treated with XDH protein] CTD PMID:21984542 NCBI chr 3:107,987,060...108,052,043
Ensembl chr 3:107,987,126...108,053,169
JBrowse link
indometacin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen affects activity EXP Indomethacin affects the activity of AGT protein CTD PMID:21127344 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
JBrowse link
G DDIT3 DNA damage inducible transcript 3 increases expression EXP Indomethacin results in increased expression of DDIT3 mRNA CTD PMID:18799549 NCBI chr 5:22,785,441...22,789,867
Ensembl chr 5:22,785,445...22,789,829
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP Indomethacin results in increased expression of HSPA5 mRNA CTD PMID:18799549 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
JBrowse link
isoxaben term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2C49 cytochrome P450 2C49 decreases response to substance EXP CYP2C49 protein results in decreased susceptibility to isoxaben CTD PMID:16315095 NCBI chr14:106,571,803...106,612,082
Ensembl chr14:106,285,173...106,612,455
JBrowse link
itraconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ABCB4 ATP binding cassette subfamily B member 4 multiple interactions EXP Itraconazole inhibits the reaction [ABCB4 protein results in increased export of Phosphatidylcholines] CTD PMID:21056966 NCBI chr 9:93,171,371...93,262,124 JBrowse link
ketoconazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP3A29 cytochrome P450 family 3 subfamily A member 29 multiple interactions EXP Ketoconazole inhibits the reaction [CYP3A29 protein results in increased chemical synthesis of 6 beta-hydroxytestosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased hydroxylation of Testosterone]; Ketoconazole inhibits the reaction [CYP3A29 protein results in increased oxidation of Nifedipine] CTD PMID:20863320 NCBI chr 3:6,738,502...6,778,121
Ensembl chr 3:6,738,486...6,778,944
JBrowse link
losartan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen affects activity EXP Losartan affects the activity of AGT protein CTD PMID:21127344 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
JBrowse link
melamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CDH2 cadherin 2 decreases expression EXP melamine results in decreased expression of CDH2 protein CTD PMID:30055240 NCBI chr 6:112,396,713...112,629,073
Ensembl chr 6:112,396,721...112,628,432
JBrowse link
G GJA1 gap junction protein alpha 1 decreases expression EXP melamine results in decreased expression of GJA1 protein CTD PMID:30055240 NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation EXP melamine results in increased phosphorylation of MAPK1 protein CTD PMID:30055240 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 increases phosphorylation EXP melamine results in increased phosphorylation of MAPK3 protein CTD PMID:30055240 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G OCLN occludin decreases expression EXP melamine results in decreased expression of OCLN protein CTD PMID:30055240 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
JBrowse link
G TJP1 tight junction protein 1 decreases expression EXP melamine results in decreased expression of TJP1 protein CTD PMID:30055240 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
JBrowse link
melatonin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased phosphorylation of AKT1 protein] CTD PMID:37120089
G ARB2A ARB2 cotranscriptional regulator A multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of ARB2A mRNA] CTD PMID:37120089 NCBI chr 2:100,477,770...100,893,594
Ensembl chr 2:100,477,775...100,893,580
JBrowse link
G ATG5 autophagy related 5 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in increased expression of ATG5 protein] CTD PMID:37120089 NCBI chr 1:72,343,950...72,520,402
Ensembl chr 1:72,270,799...72,520,396
JBrowse link
G BAX BCL2 associated X, apoptosis regulator multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of BAX protein] CTD PMID:35665993 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions
increases expression
EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of BCL2 protein]; Melatonin inhibits the reaction [Malathion results in decreased expression of BCL2 mRNA]
Melatonin results in increased expression of BCL2 mRNA
CTD PMID:31535366 PMID:37120089 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
JBrowse link
G BECN1 beclin 1 increases expression
multiple interactions
EXP Melatonin results in increased expression of BECN1 protein
Melatonin inhibits the reaction [deoxynivalenol results in increased expression of BECN1 protein]
CTD PMID:37120089 NCBI chr12:20,041,914...20,054,249
Ensembl chr12:20,041,956...20,054,373
JBrowse link
G CASP3 caspase 3 decreases expression
multiple interactions
EXP Melatonin results in decreased expression of CASP3 mRNA
Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP3 protein]
CTD PMID:31535366 PMID:35665993 NCBI chr15:45,744,320...45,753,252
Ensembl chr15:45,742,751...45,764,213
JBrowse link
G CASP8 caspase 8 multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in decreased expression of CASP8 protein] CTD PMID:35665993 NCBI chr15:104,923,659...104,948,470
Ensembl chr15:104,923,953...104,948,468
JBrowse link
G CASP9 caspase 9 multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of CASP9 protein] CTD PMID:35665993 NCBI chr 6:74,707,597...74,730,033
Ensembl chr 6:74,706,516...74,730,007
JBrowse link
G CAT catalase multiple interactions
increases activity
EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased activity of CAT protein]; Melatonin inhibits the reaction [Malathion results in decreased expression of CAT mRNA]
Melatonin results in increased activity of CAT protein
CTD PMID:31535366 PMID:37120089 NCBI chr 2:26,493,664...26,533,881
Ensembl chr 2:26,487,653...26,581,452
JBrowse link
G CHUK component of inhibitor of nuclear factor kappa B kinase complex multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of CHUK mRNA] CTD PMID:37120089 NCBI chr14:111,316,178...111,351,669
Ensembl chr14:111,315,141...111,351,868
JBrowse link
G CLDN1 claudin 1 multiple interactions
increases expression
EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of CLDN1 protein]
Melatonin results in increased expression of CLDN1 protein
CTD PMID:37120089 NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
JBrowse link
G COX7A2L cytochrome c oxidase subunit 7A2 like multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of COX7A2L mRNA] CTD PMID:35665993 NCBI chr 3:97,951,115...97,983,309
Ensembl chr 3:97,951,114...97,983,309
JBrowse link
G GPX4 glutathione peroxidase 4 increases expression EXP Melatonin results in increased expression of GPX4 mRNA CTD PMID:31535366 NCBI chr 2:77,321,568...77,323,931
Ensembl chr 2:77,320,464...77,323,931
JBrowse link
G IL18 interleukin 18 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in increased expression of IL18 mRNA] CTD PMID:37120089 NCBI chr 9:39,839,959...39,861,258
Ensembl chr 9:39,834,973...39,861,219
JBrowse link
G IL6 interleukin 6 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in increased expression of IL6 protein] CTD PMID:37120089 NCBI chr 9:91,506,421...91,510,830
Ensembl chr 9:91,506,421...91,511,263
JBrowse link
G KLF5 KLF transcription factor 5 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of KLF5 mRNA] CTD PMID:37120089 NCBI chr11:45,370,009...45,386,673
Ensembl chr11:45,369,810...45,388,314
JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in increased expression of IL1B protein] CTD PMID:37120089
G MAP1LC3B microtubule associated protein 1 light chain 3 beta multiple interactions EXP Melatonin affects the reaction [deoxynivalenol results in increased expression of and results in increased lipidation of MAP1LC3B protein] CTD PMID:37120089 NCBI chr 6:1,919,879...1,941,069
Ensembl chr 6:1,915,387...1,941,069
JBrowse link
G MAP2K1 mitogen-activated protein kinase kinase 1 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of MAP2K1 mRNA] CTD PMID:37120089 NCBI chr 1:164,381,892...164,469,313
Ensembl chr 1:164,381,845...164,471,226
JBrowse link
G MLKL mixed lineage kinase domain like pseudokinase multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of MLKL protein] CTD PMID:35665993 NCBI chr 6:12,923,846...12,951,176
Ensembl chr 6:12,924,894...12,951,173
JBrowse link
G MTOR mechanistic target of rapamycin kinase multiple interactions
decreases phosphorylation
EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased phosphorylation of MTOR protein]
Melatonin results in decreased phosphorylation of MTOR protein
CTD PMID:37120089 NCBI chr 6:71,286,989...71,412,913
Ensembl chr 6:71,286,989...71,412,888
JBrowse link
G OCLN occludin multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of OCLN protein] CTD PMID:37120089 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
JBrowse link
G PLIN2 perilipin 2 multiple interactions EXP Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PLIN2 protein] CTD PMID:31535366 NCBI chr 1:203,683,867...203,709,277
Ensembl chr 1:203,683,862...203,709,273
JBrowse link
G PPARG peroxisome proliferator activated receptor gamma multiple interactions EXP Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG mRNA]; Melatonin inhibits the reaction [Malathion results in decreased expression of PPARG protein] CTD PMID:31535366 NCBI chr13:68,301,566...68,433,951
Ensembl chr13:68,302,322...68,433,944
JBrowse link
G PTEN phosphatase and tensin homolog multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of PTEN protein] CTD PMID:35665993 NCBI chr14:99,929,590...100,021,619 JBrowse link
G RIPK1 receptor interacting serine/threonine kinase 1 multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK1 protein] CTD PMID:35665993 NCBI chr 7:1,841,143...1,880,705
Ensembl chr 7:1,841,239...1,880,699
JBrowse link
G RIPK3 receptor interacting serine/threonine kinase 3 multiple interactions EXP Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 mRNA]; Melatonin inhibits the reaction [tetrabromobisphenol A results in increased expression of RIPK3 protein] CTD PMID:35665993 NCBI chr 7:74,951,145...74,955,255
Ensembl chr 7:74,951,145...74,955,251
JBrowse link
G SOD2 superoxide dismutase 2 increases expression
multiple interactions
EXP Melatonin results in increased expression of SOD2 mRNA
Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of SOD2 mRNA]
CTD PMID:31535366 PMID:37120089 NCBI chr 1:7,679,352...7,689,564
Ensembl chr 1:7,679,352...7,689,560
JBrowse link
G TJP1 tight junction protein 1 increases expression
multiple interactions
EXP Melatonin results in increased expression of TJP1 protein
Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of TJP1 protein]
CTD PMID:37120089 NCBI chr 1:144,930,387...145,195,857
Ensembl chr 1:144,930,370...145,195,836
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in increased expression of TNF protein] CTD PMID:37120089 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,628...23,702,416
JBrowse link
G TP53 tumor protein p53 multiple interactions
decreases expression
EXP Melatonin inhibits the reaction [Malathion results in increased expression of TP53 mRNA]
Melatonin results in decreased expression of TP53 mRNA
CTD PMID:31535366 NCBI chr12:52,939,643...52,953,786
Ensembl chr12:52,939,644...52,953,818
JBrowse link
G ZFP36L2 ZFP36 ring finger protein like 2 multiple interactions EXP Melatonin inhibits the reaction [deoxynivalenol results in decreased expression of ZFP36L2 mRNA] CTD PMID:37120089 NCBI chr 3:97,200,395...97,203,094
Ensembl chr 3:97,200,407...97,204,698
JBrowse link
methimazole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FMO1 flavin containing dimethylaniline monoxygenase 1 increases metabolic processing EXP FMO1 protein results in increased metabolism of Methimazole CTD PMID:6439199 NCBI chr 9:63,860,957...63,895,086
Ensembl chr 9:63,868,064...63,895,076
JBrowse link
G TPO thyroid peroxidase decreases activity EXP Methimazole results in decreased activity of TPO protein CTD PMID:23959146 NCBI chr 3:132,384,677...132,409,750
Ensembl chr 3:132,384,583...132,409,208
JBrowse link
NAD zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALDH7A1 aldehyde dehydrogenase 7 family member A1 multiple interactions EXP NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein] CTD PMID:21296058 NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705
JBrowse link
NAD(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ALDH7A1 aldehyde dehydrogenase 7 family member A1 multiple interactions EXP NAD promotes the reaction [Hydrogen Peroxide results in decreased activity of ALDH7A1 protein] CTD PMID:21296058 NCBI chr 2:129,663,226...129,709,728
Ensembl chr 2:129,662,969...129,709,705
JBrowse link
NADP zwitterion term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G LOC110256483 carbonyl reductase [NADPH] 1-like multiple interactions
affects binding
EXP NADP inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of CBR1 protein]
NADP binds to CBR1 protein
CTD PMID:15145449 NCBI chr13:199,713,741...199,719,535 JBrowse link
NADP(+) term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G LOC110256483 carbonyl reductase [NADPH] 1-like affects binding
multiple interactions
EXP NADP binds to CBR1 protein
NADP inhibits the reaction [4-hydroxymercuribenzoate results in decreased activity of CBR1 protein]
CTD PMID:15145449 NCBI chr13:199,713,741...199,719,535 JBrowse link
panobinostat term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G BAX BCL2 associated X, apoptosis regulator multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in increased expression of BAX mRNA] CTD PMID:37980972 NCBI chr 6:54,222,341...54,228,150
Ensembl chr 6:54,222,336...54,228,140
JBrowse link
G BCL2 BCL2 apoptosis regulator multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of BCL2 mRNA] CTD PMID:37980972 NCBI chr 1:158,337,403...158,518,214
Ensembl chr 1:158,337,522...158,518,879
JBrowse link
G H2AX H2A.X variant histone multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in increased expression of H2AX protein] CTD PMID:37980972 NCBI chr 9:46,308,824...46,310,494
Ensembl chr 9:46,309,653...46,310,084
JBrowse link
G HDAC1 histone deacetylase 1 multiple interactions EXP Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 mRNA]; Panobinostat inhibits the reaction [ochratoxin A results in increased expression of HDAC1 protein] CTD PMID:29080797 NCBI chr 6:88,749,611...88,785,220
Ensembl chr 6:88,749,634...88,785,411
JBrowse link
G NANOG Nanog homeobox multiple interactions EXP [Panobinostat co-treated with Cyclophosphamide] results in increased expression of NANOG mRNA CTD PMID:37980972 NCBI chr 5:62,931,642...62,939,086
Ensembl chr 5:62,932,382...62,939,082
JBrowse link
G POU5F1 POU class 5 homeobox 1 multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of POU5F1 mRNA] CTD PMID:37980972 NCBI chr 7:23,564,654...23,570,691 JBrowse link
G SOD1 superoxide dismutase 1 multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of SOD1 mRNA] CTD PMID:37980972 NCBI chr13:195,326,573...195,335,273
Ensembl chr13:195,326,649...195,337,729
JBrowse link
G SOX2 SRY-box transcription factor 2 multiple interactions EXP Panobinostat inhibits the reaction [Cyclophosphamide results in decreased expression of SOX2 mRNA] CTD PMID:37980972 NCBI chr13:119,668,476...119,669,435
Ensembl chr13:119,668,476...119,669,435
JBrowse link
ritonavir term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G NOS3 nitric oxide synthase 3 multiple interactions
decreases expression
EXP Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 mRNA]; Masoprocol inhibits the reaction [Ritonavir results in decreased expression of NOS3 protein]; Ritonavir results in decreased expression of and results in decreased activity of NOS3 protein
Ritonavir results in decreased expression of NOS3 mRNA; Ritonavir results in decreased expression of NOS3 protein
CTD PMID:15681703 PMID:16123675 PMID:22037733 NCBI chr18:6,209,218...6,228,912
Ensembl chr18:6,209,158...6,228,943
JBrowse link
SB 203580 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AKT1 AKT serine/threonine kinase 1 multiple interactions EXP SB 203580 affects the reaction [etoxazole affects the phosphorylation of AKT1 protein] CTD PMID:31744678
G CCL2 chemokine (C-C motif) ligand 2 multiple interactions EXP SB 203580 inhibits the reaction [3,4,3',4'-tetrachlorobiphenyl results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [titanium dioxide results in increased expression of CCL2 mRNA] CTD PMID:19265715 PMID:23380242 NCBI chr12:40,798,109...40,800,013
Ensembl chr12:40,798,109...40,800,026
JBrowse link
G CLDN1 claudin 1 multiple interactions EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CLDN1 mRNA] CTD PMID:37271275 NCBI chr13:127,714,857...127,730,628
Ensembl chr13:127,712,777...127,730,657
JBrowse link
G LOC110258578 interleukin-1 beta-like multiple interactions EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] CTD PMID:37271275
G MAPK1 mitogen-activated protein kinase 1 multiple interactions EXP SB 203580 inhibits the reaction [etoxazole results in increased phosphorylation of MAPK1 protein] CTD PMID:31744678 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
JBrowse link
G MAPK14 mitogen-activated protein kinase 14 multiple interactions EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of MAPK14 mRNA] CTD PMID:37271275 NCBI chr 7:31,791,398...31,861,544
Ensembl chr 7:31,790,877...31,862,031
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions EXP SB 203580 inhibits the reaction [etoxazole results in increased phosphorylation of MAPK3 protein] CTD PMID:31744678 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
G MAPK8 mitogen-activated protein kinase 8 multiple interactions EXP [SB 203580 co-treated with etoxazole] results in increased phosphorylation of MAPK8 protein CTD PMID:31744678 NCBI chr14:88,988,914...89,108,875
Ensembl chr14:88,988,949...89,108,874
JBrowse link
G NLRP3 NLR family pyrin domain containing 3 multiple interactions EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 mRNA] CTD PMID:37271275 NCBI chr 2:56,892,241...56,977,412
Ensembl chr 2:56,892,243...56,977,228
JBrowse link
G OCLN occludin multiple interactions EXP [SB 203580 co-treated with theanine] inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of OCLN mRNA] CTD PMID:37271275 NCBI chr16:47,600,175...47,652,435
Ensembl chr16:47,600,212...47,654,033
JBrowse link
G RPS6 ribosomal protein S6 multiple interactions EXP SB 203580 affects the reaction [etoxazole affects the phosphorylation of RPS6 protein] CTD PMID:31744678 NCBI chr 1:203,444,360...203,447,643
Ensembl chr 1:203,444,450...203,451,468
JBrowse link
G RPS6KB1 ribosomal protein S6 kinase B1 multiple interactions EXP SB 203580 affects the reaction [etoxazole affects the phosphorylation of RPS6KB1 protein] CTD PMID:31744678 NCBI chr12:36,111,584...36,159,287
Ensembl chr12:36,111,653...36,160,376
JBrowse link
G STAT1 signal transducer and activator of transcription 1 multiple interactions EXP SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of STAT1 protein] CTD PMID:21783819 NCBI chr15:95,593,201...95,646,324
Ensembl chr15:95,593,211...95,646,260
JBrowse link
G STAT3 signal transducer and activator of transcription 3 multiple interactions EXP SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of STAT3 protein] CTD PMID:21783819 NCBI chr12:20,407,316...20,471,091
Ensembl chr12:20,407,233...20,472,992
JBrowse link
G VCAM1 vascular cell adhesion molecule 1 multiple interactions EXP SB 203580 inhibits the reaction [titanium dioxide results in increased expression of VCAM1 mRNA] CTD PMID:23380242 NCBI chr 4:117,496,914...117,511,211
Ensembl chr 4:117,496,920...117,511,222
JBrowse link
serotonin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G FOS Fos proto-oncogene, AP-1 transcription factor subunit increases expression
multiple interactions
EXP Serotonin results in increased expression of FOS mRNA; Serotonin results in increased expression of FOS protein
sarpogrelate inhibits the reaction [Serotonin results in increased expression of FOS mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of FOS protein]
CTD PMID:11426759 NCBI chr 7:98,449,508...98,451,971
Ensembl chr 7:98,449,349...98,455,554
JBrowse link
G JUN Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions
increases expression
EXP sarpogrelate inhibits the reaction [Serotonin results in increased expression of JUN mRNA]; sarpogrelate inhibits the reaction [Serotonin results in increased expression of JUN protein]
Serotonin results in increased expression of JUN mRNA; Serotonin results in increased expression of JUN protein
CTD PMID:11426759 NCBI chr 6:153,686,425...153,687,635
Ensembl chr 6:153,685,682...153,687,636
JBrowse link
G MAPK1 mitogen-activated protein kinase 1 increases phosphorylation
multiple interactions
EXP Serotonin results in increased phosphorylation of MAPK1 protein
sarpogrelate inhibits the reaction [Serotonin results in increased phosphorylation of MAPK1 protein]
CTD PMID:11426759 NCBI chr14:50,083,079...50,165,528
Ensembl chr14:50,082,896...50,165,513
JBrowse link
G MAPK3 mitogen-activated protein kinase 3 multiple interactions
increases phosphorylation
EXP sarpogrelate inhibits the reaction [Serotonin results in increased phosphorylation of MAPK3 protein] CTD PMID:11426759 NCBI chr 3:18,291,444...18,299,410
Ensembl chr 3:18,291,445...18,299,567
JBrowse link
sinefungin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G COMT catechol-O-methyltransferase decreases activity EXP sinefungin results in decreased activity of COMT protein CTD PMID:26577531 NCBI chr14:51,384,729...51,403,997
Ensembl chr14:51,385,738...51,403,998
JBrowse link
skatole term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 increases oxidation EXP CYP1A1 protein results in increased oxidation of Skatole CTD PMID:30599194 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
JBrowse link
G CYP2A19 cytochrome P450 family 2 subfamily A member 19 increases hydroxylation
multiple interactions
EXP CYP2A19 protein results in increased hydroxylation of Skatole
Skatole inhibits the reaction [[CYP2A19 protein results in increased hydroxylation of coumarin] which results in increased chemical synthesis of 7-hydroxycoumarin]; Skatole inhibits the reaction [CYP2A19 protein results in increased hydroxylation of coumarin]
CTD PMID:30599194 NCBI chr 6:49,056,579...49,064,111
Ensembl chr 6:49,056,578...49,064,107
JBrowse link
G CYP2E1 cytochrome P450 family 2 subfamily E member 1 multiple interactions
increases hydroxylation
EXP Skatole inhibits the reaction [[CYP2E1 protein results in increased hydroxylation of 4-nitrophenol] which results in increased chemical synthesis of 4-nitrocatechol]; Skatole inhibits the reaction [CYP2E1 protein results in increased hydroxylation of 4-nitrophenol]
CYP2E1 protein results in increased hydroxylation of Skatole
CTD PMID:30599194 NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,817
JBrowse link
G CYP2G2 cytochrome P450 family 2 subfamily G member 2 increases metabolic processing
increases abundance
EXP CYP2A6 protein results in increased metabolism of Skatole
CYP2A6 gene polymorphism results in increased abundance of Skatole
CTD PMID:10828259 PMID:15265071 NCBI chr 6:49,069,613...49,084,953 JBrowse link
sterigmatocystin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP1A1 cytochrome P450 family 1 subfamily A member 1 increases expression EXP Sterigmatocystin results in increased expression of CYP1A1 mRNA CTD PMID:20929267 NCBI chr 7:58,802,887...58,809,155
Ensembl chr 7:58,802,887...58,809,775
JBrowse link
sulfamethoxazole hydroxylamine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CALR calreticulin increases expression EXP sulfamethoxazole hydroxylamine results in increased expression of CALR protein CTD PMID:16005169 NCBI chr 2:66,098,263...66,102,074
Ensembl chr 2:66,098,229...66,102,132
JBrowse link
G HSP90B1 heat shock protein 90 beta family member 1 decreases expression EXP sulfamethoxazole hydroxylamine results in decreased expression of HSP90B1 protein CTD PMID:16005169 NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 increases expression EXP sulfamethoxazole hydroxylamine results in increased expression of HSPA5 protein CTD PMID:16005169 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
JBrowse link
sunitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GJA1 gap junction protein alpha 1 decreases expression EXP Sunitinib results in decreased expression of GJA1 protein CTD PMID:32877659 NCBI chr 1:40,988,818...41,002,129
Ensembl chr 1:40,988,528...41,002,156
JBrowse link
G TNNT2 troponin T2, cardiac type decreases expression EXP Sunitinib results in decreased expression of TNNT2 protein CTD PMID:32877659 NCBI chr10:23,749,528...23,759,696
Ensembl chr10:23,749,335...23,763,396
JBrowse link
tunicamycin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G HSP90B1 heat shock protein 90 beta family member 1 increases expression EXP Tunicamycin results in increased expression of HSP90B1 protein CTD PMID:15049342 PMID:17416481 NCBI chr 5:80,511,513...80,531,016
Ensembl chr 5:80,511,506...80,530,991
JBrowse link
G HSPA5 heat shock protein family A (Hsp70) member 5 decreases response to substance
increases expression
EXP HSPA5 results in decreased susceptibility to Tunicamycin
Tunicamycin results in increased expression of HSPA5 protein
CTD PMID:15049342 PMID:16920763 PMID:17416481 PMID:17464326 PMID:18086661 NCBI chr 1:265,930,044...265,934,959
Ensembl chr 1:265,930,045...265,934,894
JBrowse link
valsartan term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G AGT angiotensinogen decreases activity EXP Valsartan results in decreased activity of AGT protein modified form CTD PMID:7890486 NCBI chr14:59,643,030...59,656,835
Ensembl chr14:59,643,292...59,656,833
JBrowse link
zinc protoporphyrin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G GUCY1B1 guanylate cyclase 1 soluble subunit beta 1 multiple interactions EXP zinc protoporphyrin inhibits the reaction [1H-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one results in increased degradation of GUCY1B1 protein] CTD PMID:19466990 NCBI chr 8:44,544,364...44,604,690
Ensembl chr 8:44,544,179...44,604,687
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 5076
    chemical entity 5076
      molecular entity 5075
        polyatomic entity 5055
          molecule 4898
            cyclic compound 4837
              organic cyclic compound 4837
                organic heterocyclic compound 4617
                  heteroarene 135
                    (-)-Ngaione 0
                    (2-Furanylmethyl) methyl disulfide 0
                    (2R,3S,4R,4aR,7R,8S)-8-[2-(furan-3-yl)ethyl]-4a,7,8-trimethylspiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxirane]-2,3-diol 0
                    (5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone 0
                    (E)-1-(furan-2-yl)-N-(2-methylbutyl)methanimine 0
                    (E)-1-(furan-2-yl)-N-isobutylmethanimine 0
                    (E)-1-(furan-2-yl)-N-isopentylmethanimine 0
                    (E)-6-Methyl-6-(5-methyl-2-furanyl)-3-hepten-2-one 0
                    1,4-Ipomeadiol 0
                    1-(2-Furanyl)-2-propanone 0
                    1-(2-Furyl)butan-3-one 0
                    1-(3-hydroxy-2,4,4-trimethyl-1-oxido-5-thiophen-2-yl-2-imidazol-1-iumyl)ethanone 0
                    1-(6-methyl-2-pyridinyl)-N-(3-pyridinyl)-4-imidazolecarboxamide 0
                    1-Ipomeanol 0
                    1-adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester 0
                    1-azocanyl-[(2R,4R)-2-(4-hydroxybutoxy)-4-thiophen-2-yl-3,4-dihydro-2H-pyran-6-yl]methanone 0
                    12,13-Dimethyl-5,14-dioxabicyclo[9.2.1]-tetradeca-1(13),11-dien-4-one 0
                    2,3,5-Trimethylfuran 0
                    2,4-Difurfurylfuran 0
                    2,5-Dimethyl-3-(methyldithio)furan 0
                    2,5-bis(hydroxymethyl)furan monoacetate 0
                    2-(1-Pentenyl)furan 0
                    2-(12-Tridecyn-1-yl)furan 0
                    2-(2-Furanyl)-3-methyl-2-butenal 0
                    2-(2-Thienyl)ethanol 0
                    2-(2-Thienyl)furan 0
                    2-(2-Thienylsulfonyl)acetonitrile 0
                    2-(2-Thienylsulfonyl)ethanethioamide 0
                    2-(2-furanyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b][1,3]oxazin-4-one 0
                    2-(2-thienylmethylidene)hydrazine-1-carboxamide 0
                    2-(D-glycerol-1,2-dihydroxyethyl)furan 0
                    2-(Ethoxymethyl)furan 0
                    2-(Methoxymethyl)furan 0
                    2-(N-vinylacetamide)-4-hydroxymethyl-3-ene-butyrolactone 0
                    2-(Propan-2-yl)furan 0
                    2-Ethyl-4-(2-furanyl)-2-propenal 0
                    2-Ethynylthiophene 0
                    2-Furanmethanethiol 0
                    2-Furanylmethyl propanoate 0
                    2-Heptadecylfuran 0
                    2-Hexylthiophene 0
                    2-Isopropyl-5-methylfuran 0
                    2-Methyl-3-(propyldithio)furan 0
                    2-Methyl-3-furanthiol 0
                    2-Pentadecylfuran 0
                    2-Propylfuran 0
                    2-Thiopheneacrylic acid 0
                    2-[(2R,4aR,12aR)-5-methyl-8-[[(5-methyl-3-isoxazolyl)-oxomethyl]amino]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]acetic acid 0
                    2-[(Isopropylthio)methyl]furan 0
                    2-amino-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]thiazin-4-one 0
                    2-furanacetic acid 0
                    2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone 0
                    2-sulfanylidene-1,3-dithiole-4,5-dicarboxylic acid dimethyl ester 0
                    3,4-Diethylthiophene 0
                    3,4-Dihydro-5-(5-methyl-2-furanyl)-2H-pyrrole 0
                    3-(2-Fluoropropyl)thiophene 0
                    3-(2-Furanyl)-2-propenal 0
                    3-(2-Furanylmethylene)pyrrolidine 0
                    3-(3-Furanyl)-2-methyl-2-propenal 0
                    3-(4-Methyl-3-pentenyl)thiophene 0
                    3-(5-Methyl-2-furanyl)butanal 0
                    3-(5-Methyl-2-furyl)prop-2-enal 0
                    3-Ethylfuran 0
                    3-Thiophenemethanol 0
                    3-acetylamino-N-2-thienylpropanamide 0
                    4,6-dioxo-1H-1,3,5-triazine-2-carboxamide 0
                    4-(2-Furanyl)-3-buten-2-one 0
                    4-(2-Furanylmethylene)-3,4-dihydro-2H-pyrrole 0
                    4-(2-furanylmethylidene)-2-methyl-5-oxo-1-prop-2-enyl-3-pyrrolecarboxylic acid methyl ester 0
                    4-(5-methyl-2-furanyl)-2-butanone 0
                    4-[(2-Furanylmethyl)thio]-2-pentanone 0
                    4-[(E)-[hydroxymethyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide 0
                    4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide 0
                    4-[oxo-(pyridin-4-ylamino)methyl]-1H-imidazole-5-carboxylic acid ethyl ester 0
                    4-acetyl-N-[4-(4-chlorophenyl)-2-thiazolyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide 0
                    4-bromo-1-methyl-N-(2-thiazolyl)-3-pyrazolecarboxamide 0
                    4-chloro-1-methyl-N-[1-[(4-methylphenyl)methyl]-3-pyrazolyl]-3-pyrazolecarboxamide 0
                    4-chloro-N-[(4-chlorophenyl)methyl]-3-nitro-1H-pyrazole-5-carboxamide 0
                    4-methyl-2-(3-methyl-2-butenyl)-furan 0
                    5-(2-Furanyl)-3,4-dihydro-2H-pyrrole 0
                    5-(2-furanyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                    5-(2-hydroxyethyl)-2-furanacetic acid 0
                    5-(2-methylphenyl)-N-(phenylmethyl)-2-furancarboxamide 0
                    5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide 0
                    5-(3-hydroxyphenyl)-N-[2-(4-morpholinyl)ethyl]-3-isoxazolecarboxamide 0
                    5-(4-bromophenyl)-N,N-diethyl-3-isoxazolecarboxamide 0
                    5-(4-bromophenyl)-N-propan-2-yl-3-isoxazolecarboxamide 0
                    5-(4-chlorophenyl)-N-(2-furanylmethyl)-3-isoxazolecarboxamide 0
                    5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                    5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                    5-Methyl-2-(trifluoromethyl)-3-furamide 0
                    5-[(4-fluorophenyl)methylsulfonylmethyl]-N-(2-oxolanylmethyl)-2-furancarboxamide 0
                    5-[2H-Pyrrol-4-(3H)-ylidenemethyl]-2-furanmethanol 0
                    5-bromo-N-[1-(2,5-dimethylphenyl)ethyl]-2-furancarboxamide 0
                    5-bromo-N-[2-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]-2-furancarboxamide 0
                    5-bromo-N-[6-[[(5-bromo-2-furanyl)-oxomethyl]amino]-2-pyridinyl]-2-furancarboxamide 0
                    5-methyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                    5-methyl-N-(5-methyl-3-isoxazolyl)-3-isoxazolecarboxamide 0
                    5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide 0
                    5-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-isoxazolecarboxamide 0
                    5-phenyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                    6-Methyl-6-(5-methylfuran-2-yl)heptan-2-one 0
                    Amycolasporin E 0
                    Avocadenofuran 0
                    Avocadienofuran 0
                    BBT(OH)2 0
                    Bis(2,5-dimethyl-3-furanyl) disulfide 0
                    Bis(2-furanylmethyl) disulfide 0
                    Bis(2-methyl-3-furanyl)tetrasulfide 0
                    Brasilamide E 0
                    Camellimidazole D 0
                    Camellimidazole F 0
                    Di-2-furanylmethane 0
                    Diproximicin A 0
                    E-2-Methyl-5-(fur-3-yl)-pent-2-enal 0
                    Elsholtzidiol 0
                    Ethyl 3-[(2-furanylmethyl)thio]propanoate 0
                    Ethyl 3-thiopheneacetate 0
                    Furfuryl 2-methyl-3-furyl disulfide 0
                    Furfuryl acetate 0
                    Furfuryl propyl disulfide 0
                    Furfuryl thioacetate 0
                    Heptemerone C 0
                    Isoavocadienofuran 0
                    N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                    N-(2-adamantyl)-4-bromo-1-methyl-3-pyrazolecarboxamide 0
                    N-(2-cyano-1-cyclopentenyl)-1-ethyl-3-pyrazolecarboxamide 0
                    N-(2-furylmethyl)-N'-isobutylthiourea 0
                    N-(2-furylmethyl)thiourea 0
                    N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-2-furancarboxamide 0
                    N-(2-thienylmethyl)hydrazine-1-carbothioamide 0
                    N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide 0
                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(2-methylpropyl)-3-isoxazolecarboxamide 0
                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide 0
                    N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                    N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-3-isoxazolecarboxamide 0
                    N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                    N-(4-cyano-2-methyl-3-pyrazolyl)-5-(4-methylphenyl)-3-isoxazolecarboxamide 0
                    N-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-2-furancarboxamide 0
                    N-(5-chloro-2-pyridinyl)-2-ethyl-3-pyrazolecarboxamide 0
                    N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                    N-(6-tert-butyl-3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                    N-Cyclohexyl-5-(2-thienyl)-1,2-oxazole-3-carboxamide 0
                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(2R,4aR,12aR)-2-[2-(ethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-(propylamino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2R,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                    N-[(2R,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                    N-[(2S,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[(2S,4aS,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[1-(2-furanyl)ethylideneamino]carbamic acid tert-butyl ester 0
                    N-[1-[(4-fluorophenyl)methyl]-3,5-dimethyl-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                    N-[1-[(4-fluorophenyl)methyl]-3-pyrazolyl]-5-methyl-2-furancarboxamide 0
                    N-[1-[(4-fluorophenyl)methyl]-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                    N-[2-(1-cyclohexenyl)ethyl]-5-methyl-3-isoxazolecarboxamide 0
                    N-[4-(3,4-dimethylphenyl)-2-thiazolyl]-2-furancarboxamide 0
                    N-[4-(4-chlorophenyl)-2-thiazolyl]-N-[3-(diethylamino)propyl]-2-furancarboxamide 0
                    N-\{2-[(4-chlorobenzyl)thio]ethyl\}-2-furamide 0
                    N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                    N-cyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                    N-cyclopropyl-5-thiophen-2-yl-3-isoxazolecarboxamide 0
                    N-ethyl-2-Furancarboxamide 0
                    N-phenethyl-2-furamide 0
                    N1-(2-furylmethyl)-2-cyanoacetamide 0
                    Netropsin Dihydrochloride 0
                    Oxonol 0
                    PD 125375 0
                    Penicillilactone A 0
                    Phaeofuran A 0
                    Proximicin A 0
                    Proximicin F 0
                    Proximicin G 0
                    Pyrrole-2-carboxamide 0
                    S-(2-Furanylmethyl) methanethioate 0
                    S-(2-Furanylmethyl) propanethioate 0
                    TAN-868 A 0
                    Thiophene-2-thiol 0
                    Thiophene-3-carbothioamide 0
                    Trichocitrin 0
                    [4-[1-(1-cyclopentyl-5-tetrazolyl)propyl]-1-piperazinyl]-(2-furanyl)methanone 0
                    alpha-Methyl-2-furanacrolein 0
                    azaarene + 7
                    ethylmethylthiambutene 0
                    heteroaryl group + 0
                    hydracarbazine 0
                    imidazopyrimidine + 37
                    monocyclic heteroarene + 33
                    nucleobase-containing molecular entity + 27
                    penthienate 0
                    polycyclic heteroarene + 61
                    pteridines + 21
                    rufinamide 0
                    tetrapyrrole + 12
Path 2
Term Annotations click to browse term
  CHEBI ontology 5076
    subatomic particle 5067
      composite particle 5067
        hadron 5067
          baryon 5067
            nucleon 5067
              atomic nucleus 5067
                atom 5067
                  main group element atom 5037
                    p-block element atom 5034
                      carbon group element atom 4951
                        carbon atom 4950
                          organic molecular entity 4950
                            organic molecule 4898
                              organic cyclic compound 4837
                                organic heterocyclic compound 4617
                                  heteroarene 135
                                    (-)-Ngaione 0
                                    (2-Furanylmethyl) methyl disulfide 0
                                    (2R,3S,4R,4aR,7R,8S)-8-[2-(furan-3-yl)ethyl]-4a,7,8-trimethylspiro[2,3,5,6,7,8a-hexahydro-1H-naphthalene-4,2'-oxirane]-2,3-diol 0
                                    (5-phenyl-3-isoxazolyl)-(1-pyrrolidinyl)methanone 0
                                    (E)-1-(furan-2-yl)-N-(2-methylbutyl)methanimine 0
                                    (E)-1-(furan-2-yl)-N-isobutylmethanimine 0
                                    (E)-1-(furan-2-yl)-N-isopentylmethanimine 0
                                    (E)-6-Methyl-6-(5-methyl-2-furanyl)-3-hepten-2-one 0
                                    1,4-Ipomeadiol 0
                                    1-(2-Furanyl)-2-propanone 0
                                    1-(2-Furyl)butan-3-one 0
                                    1-(3-hydroxy-2,4,4-trimethyl-1-oxido-5-thiophen-2-yl-2-imidazol-1-iumyl)ethanone 0
                                    1-(6-methyl-2-pyridinyl)-N-(3-pyridinyl)-4-imidazolecarboxamide 0
                                    1-Ipomeanol 0
                                    1-adamantanecarboxylic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester 0
                                    1-azocanyl-[(2R,4R)-2-(4-hydroxybutoxy)-4-thiophen-2-yl-3,4-dihydro-2H-pyran-6-yl]methanone 0
                                    12,13-Dimethyl-5,14-dioxabicyclo[9.2.1]-tetradeca-1(13),11-dien-4-one 0
                                    2,3,5-Trimethylfuran 0
                                    2,4-Difurfurylfuran 0
                                    2,5-Dimethyl-3-(methyldithio)furan 0
                                    2,5-bis(hydroxymethyl)furan monoacetate 0
                                    2-(1-Pentenyl)furan 0
                                    2-(12-Tridecyn-1-yl)furan 0
                                    2-(2-Furanyl)-3-methyl-2-butenal 0
                                    2-(2-Thienyl)ethanol 0
                                    2-(2-Thienyl)furan 0
                                    2-(2-Thienylsulfonyl)acetonitrile 0
                                    2-(2-Thienylsulfonyl)ethanethioamide 0
                                    2-(2-furanyl)-6,7,8,9-tetrahydro-5H-cyclohepta[2,3]thieno[2,4-b][1,3]oxazin-4-one 0
                                    2-(2-thienylmethylidene)hydrazine-1-carboxamide 0
                                    2-(D-glycerol-1,2-dihydroxyethyl)furan 0
                                    2-(Ethoxymethyl)furan 0
                                    2-(Methoxymethyl)furan 0
                                    2-(N-vinylacetamide)-4-hydroxymethyl-3-ene-butyrolactone 0
                                    2-(Propan-2-yl)furan 0
                                    2-Ethyl-4-(2-furanyl)-2-propenal 0
                                    2-Ethynylthiophene 0
                                    2-Furanmethanethiol 0
                                    2-Furanylmethyl propanoate 0
                                    2-Heptadecylfuran 0
                                    2-Hexylthiophene 0
                                    2-Isopropyl-5-methylfuran 0
                                    2-Methyl-3-(propyldithio)furan 0
                                    2-Methyl-3-furanthiol 0
                                    2-Pentadecylfuran 0
                                    2-Propylfuran 0
                                    2-Thiopheneacrylic acid 0
                                    2-[(2R,4aR,12aR)-5-methyl-8-[[(5-methyl-3-isoxazolyl)-oxomethyl]amino]-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]acetic acid 0
                                    2-[(Isopropylthio)methyl]furan 0
                                    2-amino-5,6,7,8-tetrahydro-[1]benzothiolo[2,3-d][1,3]thiazin-4-one 0
                                    2-furanacetic acid 0
                                    2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone 0
                                    2-sulfanylidene-1,3-dithiole-4,5-dicarboxylic acid dimethyl ester 0
                                    3,4-Diethylthiophene 0
                                    3,4-Dihydro-5-(5-methyl-2-furanyl)-2H-pyrrole 0
                                    3-(2-Fluoropropyl)thiophene 0
                                    3-(2-Furanyl)-2-propenal 0
                                    3-(2-Furanylmethylene)pyrrolidine 0
                                    3-(3-Furanyl)-2-methyl-2-propenal 0
                                    3-(4-Methyl-3-pentenyl)thiophene 0
                                    3-(5-Methyl-2-furanyl)butanal 0
                                    3-(5-Methyl-2-furyl)prop-2-enal 0
                                    3-Ethylfuran 0
                                    3-Thiophenemethanol 0
                                    3-acetylamino-N-2-thienylpropanamide 0
                                    4,6-dioxo-1H-1,3,5-triazine-2-carboxamide 0
                                    4-(2-Furanyl)-3-buten-2-one 0
                                    4-(2-Furanylmethylene)-3,4-dihydro-2H-pyrrole 0
                                    4-(2-furanylmethylidene)-2-methyl-5-oxo-1-prop-2-enyl-3-pyrrolecarboxylic acid methyl ester 0
                                    4-(5-methyl-2-furanyl)-2-butanone 0
                                    4-[(2-Furanylmethyl)thio]-2-pentanone 0
                                    4-[(E)-[hydroxymethyl(methyl)amino]diazenyl]-1H-imidazole-5-carboxamide 0
                                    4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide 0
                                    4-[oxo-(pyridin-4-ylamino)methyl]-1H-imidazole-5-carboxylic acid ethyl ester 0
                                    4-acetyl-N-[4-(4-chlorophenyl)-2-thiazolyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide 0
                                    4-bromo-1-methyl-N-(2-thiazolyl)-3-pyrazolecarboxamide 0
                                    4-chloro-1-methyl-N-[1-[(4-methylphenyl)methyl]-3-pyrazolyl]-3-pyrazolecarboxamide 0
                                    4-chloro-N-[(4-chlorophenyl)methyl]-3-nitro-1H-pyrazole-5-carboxamide 0
                                    4-methyl-2-(3-methyl-2-butenyl)-furan 0
                                    5-(2-Furanyl)-3,4-dihydro-2H-pyrrole 0
                                    5-(2-furanyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                                    5-(2-hydroxyethyl)-2-furanacetic acid 0
                                    5-(2-methylphenyl)-N-(phenylmethyl)-2-furancarboxamide 0
                                    5-(3-chlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide 0
                                    5-(3-hydroxyphenyl)-N-[2-(4-morpholinyl)ethyl]-3-isoxazolecarboxamide 0
                                    5-(4-bromophenyl)-N,N-diethyl-3-isoxazolecarboxamide 0
                                    5-(4-bromophenyl)-N-propan-2-yl-3-isoxazolecarboxamide 0
                                    5-(4-chlorophenyl)-N-(2-furanylmethyl)-3-isoxazolecarboxamide 0
                                    5-(4-chlorophenyl)-N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                                    5-(4-methylphenyl)-N-(3-pyridinylmethyl)-3-isoxazolecarboxamide 0
                                    5-Methyl-2-(trifluoromethyl)-3-furamide 0
                                    5-[(4-fluorophenyl)methylsulfonylmethyl]-N-(2-oxolanylmethyl)-2-furancarboxamide 0
                                    5-[2H-Pyrrol-4-(3H)-ylidenemethyl]-2-furanmethanol 0
                                    5-bromo-N-[1-(2,5-dimethylphenyl)ethyl]-2-furancarboxamide 0
                                    5-bromo-N-[2-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]-2-furancarboxamide 0
                                    5-bromo-N-[6-[[(5-bromo-2-furanyl)-oxomethyl]amino]-2-pyridinyl]-2-furancarboxamide 0
                                    5-methyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                                    5-methyl-N-(5-methyl-3-isoxazolyl)-3-isoxazolecarboxamide 0
                                    5-methyl-N-[4-(2-pyridinyl)-2-thiazolyl]-2-furancarboxamide 0
                                    5-methyl-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-isoxazolecarboxamide 0
                                    5-phenyl-N-(3-pyridinyl)-3-isoxazolecarboxamide 0
                                    6-Methyl-6-(5-methylfuran-2-yl)heptan-2-one 0
                                    Amycolasporin E 0
                                    Avocadenofuran 0
                                    Avocadienofuran 0
                                    BBT(OH)2 0
                                    Bis(2,5-dimethyl-3-furanyl) disulfide 0
                                    Bis(2-furanylmethyl) disulfide 0
                                    Bis(2-methyl-3-furanyl)tetrasulfide 0
                                    Brasilamide E 0
                                    Camellimidazole D 0
                                    Camellimidazole F 0
                                    Di-2-furanylmethane 0
                                    Diproximicin A 0
                                    E-2-Methyl-5-(fur-3-yl)-pent-2-enal 0
                                    Elsholtzidiol 0
                                    Ethyl 3-[(2-furanylmethyl)thio]propanoate 0
                                    Ethyl 3-thiopheneacetate 0
                                    Furfuryl 2-methyl-3-furyl disulfide 0
                                    Furfuryl acetate 0
                                    Furfuryl propyl disulfide 0
                                    Furfuryl thioacetate 0
                                    Heptemerone C 0
                                    Isoavocadienofuran 0
                                    N,N-dicyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                                    N-(2-adamantyl)-4-bromo-1-methyl-3-pyrazolecarboxamide 0
                                    N-(2-cyano-1-cyclopentenyl)-1-ethyl-3-pyrazolecarboxamide 0
                                    N-(2-furylmethyl)-N'-isobutylthiourea 0
                                    N-(2-furylmethyl)thiourea 0
                                    N-(2-sulfanylidene-3H-1,3,4-thiadiazol-5-yl)-2-furancarboxamide 0
                                    N-(2-thienylmethyl)hydrazine-1-carbothioamide 0
                                    N-(3,3,5-trimethylcyclohexyl)-1H-1,2,4-triazole-5-carboxamide 0
                                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-(2-methylpropyl)-3-isoxazolecarboxamide 0
                                    N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-4-nitro-3-isoxazolecarboxamide 0
                                    N-(3-cyano-5,6-dihydro-4H-cyclopenta[b]thiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                                    N-(3-cyano-6-methyl-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-methyl-3-isoxazolecarboxamide 0
                                    N-(3-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                                    N-(4-cyano-2-methyl-3-pyrazolyl)-5-(4-methylphenyl)-3-isoxazolecarboxamide 0
                                    N-(4-oxo-2-thieno[3,2-d][1,3]thiazinyl)-2-furancarboxamide 0
                                    N-(5-chloro-2-pyridinyl)-2-ethyl-3-pyrazolecarboxamide 0
                                    N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-furancarboxamide 0
                                    N-(6-tert-butyl-3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-5-cyclopropyl-3-isoxazolecarboxamide 0
                                    N-Cyclohexyl-5-(2-thienyl)-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3R)-2-[(dimethylamino)methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,4aR,12aR)-2-[2-(ethylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-(propylamino)ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aR)-5-methyl-6-oxo-2-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2R,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-1,2-oxazole-3-carboxamide 0
                                    N-[(2R,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,3R)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3R)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[(dimethylamino)methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,3S)-2-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-2,5-dimethyl-3-pyrazolecarboxamide 0
                                    N-[(2S,4aR,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aR,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aS,12aR)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[(2S,4aS,12aS)-2-[2-(cyclopentylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[1-(2-furanyl)ethylideneamino]carbamic acid tert-butyl ester 0
                                    N-[1-[(4-fluorophenyl)methyl]-3,5-dimethyl-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                                    N-[1-[(4-fluorophenyl)methyl]-3-pyrazolyl]-5-methyl-2-furancarboxamide 0
                                    N-[1-[(4-fluorophenyl)methyl]-4-pyrazolyl]-5-(2-furanyl)-3-isoxazolecarboxamide 0
                                    N-[2-(1-cyclohexenyl)ethyl]-5-methyl-3-isoxazolecarboxamide 0
                                    N-[4-(3,4-dimethylphenyl)-2-thiazolyl]-2-furancarboxamide 0
                                    N-[4-(4-chlorophenyl)-2-thiazolyl]-N-[3-(diethylamino)propyl]-2-furancarboxamide 0
                                    N-\{2-[(4-chlorobenzyl)thio]ethyl\}-2-furamide 0
                                    N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide 0
                                    N-cyclohexyl-5-propyl-3-isoxazolecarboxamide 0
                                    N-cyclopropyl-5-thiophen-2-yl-3-isoxazolecarboxamide 0
                                    N-ethyl-2-Furancarboxamide 0
                                    N-phenethyl-2-furamide 0
                                    N1-(2-furylmethyl)-2-cyanoacetamide 0
                                    Netropsin Dihydrochloride 0
                                    Oxonol 0
                                    PD 125375 0
                                    Penicillilactone A 0
                                    Phaeofuran A 0
                                    Proximicin A 0
                                    Proximicin F 0
                                    Proximicin G 0
                                    Pyrrole-2-carboxamide 0
                                    S-(2-Furanylmethyl) methanethioate 0
                                    S-(2-Furanylmethyl) propanethioate 0
                                    TAN-868 A 0
                                    Thiophene-2-thiol 0
                                    Thiophene-3-carbothioamide 0
                                    Trichocitrin 0
                                    [4-[1-(1-cyclopentyl-5-tetrazolyl)propyl]-1-piperazinyl]-(2-furanyl)methanone 0
                                    alpha-Methyl-2-furanacrolein 0
                                    azaarene + 7
                                    ethylmethylthiambutene 0
                                    heteroaryl group + 0
                                    hydracarbazine 0
                                    imidazopyrimidine + 37
                                    monocyclic heteroarene + 33
                                    nucleobase-containing molecular entity + 27
                                    penthienate 0
                                    polycyclic heteroarene + 61
                                    pteridines + 21
                                    rufinamide 0
                                    tetrapyrrole + 12
paths to the root